Home > Insider Trading > Filing (0000950170-24-041301)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693011	Inozyme Pharma Inc.	INZY	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1688192	A Douglas Treco	C/O Inozyme Pharma, Inc. 321 Summer Street Suite 400 Boston MA 02210	Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-04-01	25,000	$0.00	28,188	No	4	M	Direct
Common Stock	Disposition	2024-04-02	7,523	$6.94	20,665	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-04-01	25,000	$0.00	25,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
75,000			No	4	M	Direct

Footnotes

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
Includes 3,188 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan on March 28, 2024.
This transaction was effected pursuant to a durable automatic sale instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date.